IGC Pharma Inc IGC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
-
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
-
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
-
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
-
New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA
-
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
-
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
-
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
Trading Information
- Previous Close Price
- $0.28
- Day Range
- $0.27–0.28
- 52-Week Range
- $0.24–0.50
- Bid/Ask
- $0.27 / $0.28
- Shares Outstanding
- 104.37M
- Market Cap
- $28.39M
- Volume/Avg
- 462,229 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer’s disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 70
- Website
- https://www.igcinc.us
Valuation
|
Metric
|
IGC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.49 |
Price/Sales | 21.37 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IGC
|
|---|---|
Quick Ratio | 0.12 |
Current Ratio | 0.40 |
Interest Coverage | — |
Quick Ratio
IGC
Profitability
|
Metric
|
IGC
|
|---|---|
Return on Assets (Normalized) | −37.84% |
Return on Equity (Normalized) | −50.39% |
Return on Invested Capital (Normalized) | −48.06% |
Return on Assets
IGC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@b%G%?$ | LOCK|hdgK^ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?D^&qs | LOCK|T>cj | $70B | |||
| argenx SE ADR
ARGX
| LOCK|>BD%Hc | LOCK|#< | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!S$sM%! | LOCK|XtQ?S | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Zc??Td> | LOCK|S$B | $36B | |||
| Moderna Inc
MRNA
| LOCK|#q^Cvl | LOCK|W# | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|lNs&#z?r | LOCK|%SBP< | $25B | |||
| Incyte Corp
INCY
| LOCK|j%g#$$ | LOCK|mcc | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Nh^?sh | LOCK|qc | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|hLyNKm | LOCK|!l | $17B |
United States